EZR Primary Antibody
|Aliases||CVL; CVIL; VIL2; HEL-S-105|
|Formulation||Purified antibody in PBS with 0.05% sodium azide|
|Immunogen||Purified recombinant fragment of human EZR (AA: 292-464) expressed in E. Coli.|
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|Species Reactivity||Human, Mouse, Monkey|
|ICC (Immunocytochemistry)||1/100 - 1/400|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||1/500 - 1/2000|
Figure 1: Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);
Figure 2:Western blot analysis using EZR mAb against human EZR (AA: 292-464) recombinant protein. (Expected MW is 47.1 kDa)
Figure 3:Western blot analysis using EZR mAb against HEK293 (1) and EZR (AA: 292-464)-hIgGFc transfected HEK293 (2) cell lysate.
Figure 4:Western blot analysis using EZR mouse mAb against MCF-7 (1), Hela (2), A431 (3), Hek293 (4), SK-N-SH (5), Jurkat (6), HepG2 (7), NIH/3T3 (8), and Cos7 (9) cell lysate.
Figure 5:Immunofluorescence analysis of A549 cells using EZR mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)
Figure 6:Flow cytometric analysis of MCF-7 cells using EZR mouse mAb (green) and negative control (red).
Figure 7:Flow cytometric analysis of Hela cells using EZR mouse mAb (green) and negative control (red).
|Description||The cytoplasmic peripheral membrane protein encoded by this gene functions as a protein-tyrosine kinase substrate in microvilli. As a member of the ERM protein family, this protein serves as an intermediate between the plasma membrane and the actin cytoskeleton. This protein plays a key role in cell surface structure adhesion, migration and organization, and it has been implicated in various human cancers. A pseudogene located on chromosome 3 has been identified for this gene. Alternatively spliced variants have also been described for this gene.|
|References (references)||1.BMC Cancer. 2013 Nov 4;13:520. |
2.Cell Oncol (Dordr). 2013 Dec;36(6):485-91.